Meitav Dash Investments Ltd. Takes Position in AbbVie Inc. (NYSE:ABBV)
Meitav Dash Investments Ltd. Takes Position in AbbVie Inc. (NYSE:ABBV)
Meitav Dash Investments Ltd. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 9,741 shares of the company's stock, valued at approximately $1,579,000.
據艾伯維公司在最近提交給美國證券交易委員會(Securities&Exchange Commission)的文件中説，該公司在第一季度購買了新的艾伯維公司股票頭寸。該公司購買了9,741股該公司股票，價值約1,579,000美元。
Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in AbbVie by 1.1% during the fourth quarter. BlackRock Inc. now owns 128,197,554 shares of the company's stock worth $17,357,949,000 after acquiring an additional 1,358,115 shares during the last quarter. State Street Corp lifted its position in AbbVie by 3.4% during the fourth quarter. State Street Corp now owns 79,357,705 shares of the company's stock worth $10,745,033,000 after acquiring an additional 2,597,076 shares during the last quarter. Geode Capital Management LLC lifted its position in AbbVie by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,518,946 shares of the company's stock worth $3,850,573,000 after acquiring an additional 758,354 shares during the last quarter. Norges Bank acquired a new stake in AbbVie during the fourth quarter worth approximately $2,433,269,000. Finally, Nuveen Asset Management LLC raised its position in shares of AbbVie by 12.2% in the fourth quarter. Nuveen Asset Management LLC now owns 16,331,749 shares of the company's stock valued at $2,211,319,000 after buying an additional 1,771,090 shares in the last quarter. Institutional investors own 67.03% of the company's stock.
其他對衝基金和其他機構投資者也買賣了該公司的股票。貝萊德股份有限公司在第四季度將其在艾伯維的持倉提高了1.1%。貝萊德股份有限公司在上個季度增持了1,358,115股後，目前持有128,197,554股該公司股票，價值17,357,949,000美元。道富集團在第四季度將其在AbbVie的頭寸提高了3.4%。道富銀行目前持有79,357,705股該公司股票，價值10,745,033,000美元，上一季度又收購了2,597,076股。Geode Capital Management LLC在第四季度將其在AbbVie的頭寸提高了2.7%。Geode Capital Management LLC在上個季度增持了758,354股後，現在擁有28,518,946股該公司股票，價值3,850,573,000美元。挪威銀行在第四季度收購了AbbVie的新股份，價值約2433269,000美元。最後，Nuveen Asset Management LLC在第四季度將其在AbbVie股票的持倉提高了12.2%。Nuveen Asset Management LLC現在擁有16,331,749股該公司股票，價值2,211,319,000美元，上個季度又購買了1,771,090股。機構投資者持有該公司67.03%的股份。
Analyst Ratings Changes
分析師評級發生變化
Several research analysts have commented on ABBV shares. Piper Sandler lowered their price objective on shares of AbbVie from $160.00 to $155.00 in a research report on Friday, July 29th. The Goldman Sachs Group boosted their price objective on shares of AbbVie from $122.00 to $140.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 12th. SVB Leerink assumed coverage on shares of AbbVie in a report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 target price on the stock. Morgan Stanley dropped their price objective on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating on the stock in a report on Monday, August 1st. Finally, Wells Fargo & Company upped their price objective on shares of AbbVie from $165.00 to $200.00 in a report on Monday, May 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $160.50.
幾位研究分析師對ABBV的股票發表了評論。在7月29日星期五的一份研究報告中，派珀·桑德勒將艾伯維的股票目標價從160.00美元下調至155.00美元。高盛夫婦將艾伯維股票的目標價從122.00美元上調至140.00美元，並在週二的一份研究報告中給予該股“中性”評級。SVB Leerink在5月23日星期一的一份報告中對AbbVie的股票進行了報道。他們對該股給予了“表現不佳”的評級和140.00美元的目標價。在8月1日週一的一份報告中，摩根士丹利將艾伯維股票的目標價從191.00美元下調至188.00美元，並對該股設定了“增持”評級。最後，富國銀行在5月2日星期一的一份報告中將艾伯維股票的目標價從165.00美元上調至200.00美元。一名研究分析師對該股的評級為賣出，6名分析師發佈了持有評級，9名分析師給予了買入評級，一名分析師給予了該公司強烈的買入評級。根據MarketBeat.com的數據，該股目前的普遍評級為“適度買入”，平均目標價為160.50美元。
AbbVie Stock Performance
艾伯維股票表現
AbbVie (NYSE:ABBV – Get Rating) last posted its quarterly earnings data on Friday, July 29th. The company reported $3.37 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.06. The firm had revenue of $14.58 billion for the quarter, compared to analysts' expectations of $14.64 billion. AbbVie had a net margin of 22.03% and a return on equity of 157.31%. The business's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $3.11 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
艾伯維(紐約證券交易所代碼：ABBV-GET Rating)上一次公佈季度收益數據是在7月29日星期五。該公司公佈本季度每股收益為3.37美元，比普遍預期的3.31美元高出0.06美元。該公司當季營收為145.8億美元，高於分析師預期的146.4億美元。艾伯維的淨利潤率為22.03%，股本回報率為157.31%。該業務的季度收入同比增長了4.5%。去年同期，該公司公佈的每股收益為3.11美元。股票研究分析師平均預計，AbbVie Inc.本財年每股收益為14.05美元。
AbbVie Dividend Announcement
AbbVie股息公告
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Friday, July 15th will be issued a dividend of $1.41 per share. This represents a $5.64 annualized dividend and a dividend yield of 4.09%. The ex-dividend date is Thursday, July 14th. AbbVie's dividend payout ratio is currently 79.89%.
該公司最近還宣佈了季度股息，將於8月15日星期一支付。7月15日(星期五)登記在冊的投資者將獲得每股1.41美元的股息。這意味着年化股息為5.64美元，股息收益率為4.09%。除股息日期為7月14日星期四。艾伯維的股息支付率目前為79.89%。
Insider Activity at AbbVie
艾伯維的內幕活動
In other AbbVie news, EVP Henry O. Gosebruch sold 83,960 shares of the firm's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $155.00, for a total value of $13,013,800.00. Following the sale, the executive vice president now owns 16,623 shares of the company's stock, valued at approximately $2,576,565. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other AbbVie news, Vice Chairman Michael Severino sold 100,000 shares of the firm's stock in a transaction on Monday, May 9th. The shares were sold at an average price of $150.28, for a total value of $15,028,000.00. Following the sale, the insider now owns 152,103 shares of the company's stock, valued at approximately $22,858,038.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Henry O. Gosebruch sold 83,960 shares of AbbVie stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the sale, the executive vice president now directly owns 16,623 shares in the company, valued at approximately $2,576,565. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 363,761 shares of company stock valued at $55,528,771. Insiders own 0.08% of the company's stock.
在AbbVie的其他新聞中，執行副總裁Henry O.Gosebruch在5月16日星期一的一筆交易中出售了83,960股公司股票。這些股票的平均價格為155.00美元，總價值為13,013,800.00美元。出售股份後，執行副總裁總裁現在持有該公司16623股股票，價值約2576565美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，可以通過這個超級鏈接獲得。在AbbVie的其他新聞中，副董事長Michael Severino在5月9日星期一的一筆交易中出售了10萬股公司股票。這些股票的平均價格為150.28美元，總價值為150,028,000.00美元。出售後，這位內部人士現在擁有152,103股該公司股票，價值約22,858,038.84美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，可以通過這個超級鏈接獲得。此外，執行副總裁亨利·O·古斯布魯赫在5月16日星期一的交易中出售了83,960股AbbVie股票。這些股票以155.00美元的平均價格出售，總成交金額為13,013,800.00美元。出售後，執行副總裁總裁現在直接持有該公司16,623股股份，價值約2,576,565美元。此次拍賣的披露信息可在此處找到。在過去的90天裏，內部人士出售了363,761股公司股票，價值55,528,771美元。內部人士持有該公司0.08%的股份。
AbbVie Profile
AbbVie個人資料
(Get Rating)
(獲取評級)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯維公司在世界各地發現、開發、製造和銷售藥品。該公司提供HUMIRA，用於注射治療自身免疫和腸道Behçet‘s疾病；SKYRIZI用於治療成人中到重度斑塊型牛皮癬；RINVOQ，用於治療成人患者的中到重度活動性類風濕性關節炎；IMBRUVICA，用於治療成人慢性淋巴細胞白血病和小淋巴細胞淋巴瘤；以及VENCLEXTA，用於治療成人慢性丙型肝炎病毒基因1-6感染。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免費獲取StockNews.com關於AbbVie的研究報告(ABBV)
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望，而且它很便宜
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Get Rating).
想看看其他對衝基金持有ABBV嗎？訪問HoldingsChannel.com獲取艾伯維公司的最新13F文件和內幕交易。
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對AbbVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。